Teriflunomide: a novel oral treatment for relapsing multiple sclerosis

Bibliography

• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
   PubMed Web of Science ®Google Scholar
• Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012;366:339-47
   PubMed Web of Science ®Google Scholar
• Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756-67
   PubMed Web of Science ®Google Scholar
• Freedman MS, Boster A, Fernandez O, et al. Long-term efficacy, safety and tolerability of ponesimod in patients with relapsing–remitting multiple sclerosis. Neurology 2013;80:P01.156
   Google Scholar
• Vollmer T, Selmaj K, Bar-Or A, et al. A double-blind, placebo-controlled, Phase 2, 26-week DreaMS trial of a selective S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis. Neurology 2012;78(Suppl 1):013
   PubMedGoogle Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-8
   PubMed Web of Science ®Google Scholar
• Van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368:1658-9; Erratum, N Engl J Med 2013;368:1950
   PubMed Web of Science ®Google Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9
   PubMed Web of Science ®Google Scholar
• Warnke C, Meyer zuHörste G, Hartung H, et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2009;5:333-40
   PubMed Web of Science ®Google Scholar
• Li L, Liu J, Delohery T, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol 2013;265:82-90
   PubMed Web of Science ®Google Scholar
• Leist T, Freedman MS, Kappos L, et al. Pooled safety data from three placebo-controlled teriflunomide studies. Mult Scler 2013;19:74 P633
   Web of Science ®Google Scholar
• Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 2013;81:552-8
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Larouche R, Legrand B, et al. Immune response to neoantigen and recall antigens in healthy subjects receiving teriflunomide. Mult Scler 2013;19:74 P622
   Web of Science ®Google Scholar
• Posevitz V, Chudyka D, Kurth F, et al. The anti-proliferative effect of teriflunomide correlates with antigen affinity. Mult Scler 2013;19:74 P974
   Web of Science ®Google Scholar
• Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 2012;142:49-56
   PubMed Web of Science ®Google Scholar
• Merrill JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioural, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009;256:89-103
   PubMed Web of Science ®Google Scholar
• Iglesias-Bregna D, Hanak S, Ji Z, et al. Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2013;347:203-11
   PubMed Web of Science ®Google Scholar
• Ringheim GE, Lee L, Laws-Ricker L, et al. Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis. Front Neurol 2013;30(4):169
   Google Scholar
• Pachner A, Keyes L, Gilli F. Teriflunomide treatment decreases chemokine expression in the CNS in the Theiler's virus-induced demyelinating disease model of multiple sclerosis. Mult Scler 2013;19:74 P369
   Web of Science ®Google Scholar
• Limsakun T, Menguy-Vacheron F. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. Neurology 2010;74:P05. 032
   Web of Science ®Google Scholar
• Limsakun T, Menguy-Vacheron F. Effects of cholestyramine on the elimination of teriflunomide in healthy male volunteers. Mult Scler 2011;16:P11
   Web of Science ®Google Scholar
• Miller A, Turpault S, Menguy-Vacheron F. Rapid elimination procedure of teriflunomide with cholestyramine or activated charcoal. In Fourth Cooperative Meeting of CMSC and ACTRIMS; 30 May – 2 June 2012; San Diego, CA, USA. P10
   Google Scholar
• O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900
   PubMed Web of Science ®Google Scholar
• O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler 2013;19:1310-19
   PubMed Web of Science ®Google Scholar
• Miller AE, O'Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler 2012;18:1625-32
   PubMed Web of Science ®Google Scholar
• Freedman MS, O'Connor P, Wolinsky JS, et al. Teriflunomide increases the proportion of patients free from disease activity in the TEMSO phase III study. Neurology 2012;78:PD5. 00
   Web of Science ®Google Scholar
• O'Connor P, Lublin FD, Wolinsky JS, et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol 2013;260:2472-80
   PubMed Web of Science ®Google Scholar
• Freedman MS, Wolinsky J, Comi G, et al. Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. Mult Scler 2013;19:74 P544
   Google Scholar
• Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13(3):247-56
   PubMed Web of Science ®Google Scholar
• O'Connor P, Lublin F, Wolinsky J, et al. Teriflunomide reduces relapse-related sequelae, hospitalizations and corticosteroid use: a post-hoc analysis of the phase 3 TOWER study. Neurology 2013;80:P07. 109
   Web of Science ®Google Scholar
• Kappos L, Comi G, Freedman MS, et al. Pooled efficacy data from two phase 3 placebo-controlled trials of oral, once-daily teriflunomide. Mult Scler 2013;19:74 P618
   Web of Science ®Google Scholar
• Macdonell R, Lublin F, Comi G, et al. Teriflunomide reduces relapse-related sequelae, severe relapses, hospitalizations and corticosteroid use: pooled data from the phase 3 TEMSO and TOWER studies. Mult Scler 2013;19:74 P1095
   Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-506
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomized, controlled phase 3 trial. Mult Scler 2013. [ Epub ahead of print], doi:10.1177/1352458513507821
   Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
   PubMed Web of Science ®Google Scholar
• Miller A, Wolinsky J, Kappos L, et al. TOPIC main outcomes: efficacy and safety of once-daily oral teriflunomide in patients with clinically isolated syndrome. Mult Scler 2013;19:18 99
   Web of Science ®Google Scholar
• Freedman MS, Wolinsky JS, Wamil B, et al. Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis. Int J MS Care 2011;13:17
   Google Scholar
• Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis. A randomized phase II trial. Neurology 2012;78:1877-85
   PubMed Web of Science ®Google Scholar
• Freedman MS, Cheng S, Truffinet P, et al. TERACLES study design: teriflunomide as adjunctive therapy with interferon-beta in patients with relapsing multiple sclerosis. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS; 30 May – 2 June 2012; San Diego, CA, USA. P9
   Google Scholar
• Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012;18:1278-89
   PubMed Web of Science ®Google Scholar
• Freedman MS, Delhay J-L, Benamor M. Gastrointestinal symptoms infrequently led to discontinuation of teriflunomide therapy. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS; 30 May – 2 June 2012; San Diego, CA, USA. P8
   Google Scholar
• Freedman MS, Confavreux C, Comi G, et al. Hair thinning associated with teriflunomide therapy is manageable. Poster presentation at the Fourth Cooperative Meeting of CMSC and ACTRIMS; 30 May – 2 June 2012; San Diego, CA, USA. P7
   Google Scholar
• Kieseier B, Stüve O, Benamor M, et al. Updated pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. Mult Scler 2013;19:74 P541
   Web of Science ®Google Scholar
• Davenport L, Czich A, Turpault S. Teriflunomide: no effects on sperm DNA. Mult Scler 2013;19:559 P1187
   PubMed Web of Science ®Google Scholar
• Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503
   PubMed Web of Science ®Google Scholar
• Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012;64:2085-94
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
   PubMed Web of Science ®Google Scholar
• CDEC Final recommendation - Dimethyl Fumarate. 2013. Available from: http://www.cadth.ca/media/cdr/complete/cdr_complete_Tecfidera_September_30-13.pdf [Last accessed 23 January 2014]
   Google Scholar